Cargando…

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition

BACKGROUND: Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein, the study aimed to test whether e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tie, Chunmiao, Gao, Kanglu, Zhang, Na, Zhang, Songzhao, Shen, Jiali, Xie, Xiaojie, Wang, Jian-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640821/
https://www.ncbi.nlm.nih.gov/pubmed/26555472
http://dx.doi.org/10.1371/journal.pone.0142430
_version_ 1782400122160676864
author Tie, Chunmiao
Gao, Kanglu
Zhang, Na
Zhang, Songzhao
Shen, Jiali
Xie, Xiaojie
Wang, Jian-an
author_facet Tie, Chunmiao
Gao, Kanglu
Zhang, Na
Zhang, Songzhao
Shen, Jiali
Xie, Xiaojie
Wang, Jian-an
author_sort Tie, Chunmiao
collection PubMed
description BACKGROUND: Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein, the study aimed to test whether ezetimibe alone would exhibit similar effects as statin and the combination therapy would be necessary in a moderate lesion size. METHODS AND RESULTS: ApoE-/- male mice that were fed a saturated-fat supplemented diet were randomly assigned to different therapeutic regimens: vehicle, ezetimibe alone (10 mg/kg/day), atorvastatin (20 mg/kg/day) or combination of ezetimibe and atorvastatin through the drinking water. On 28 days, mice were sacrificed and aorta and sera were collected to analyze the atherosclerotic lesion and blood lipid and cholesterol levels. As a result, ezetimibe alone exerted similar protective effects on atherosclerotic lesion sizes as atorvastatin, which was mediated by lowering serum cholesterol concentrations, inhibiting macrophage accumulation in the lesions and reducing circulatory inflammatory cytokines, such as monocyte chemoattractant protein (MCP-1) and tumor necrosis factor (TNF-α). In contrast to ezetimibe administration, atorvastatin alone attenuated atherosclerotic lesion which is dependent on its anti-inflammation effects. There were no significance differences in lesion areas and serum concentrations of cholesterol, oxidized LDL and inflammatory cytokines between combination therapy and monotherapy (either ezetimibe or atorvastatin). There were significant correlations between the lesion areas and serum concentrations of cholesterol, MCP-1 and TNF-α, respectively. However, there were no significant correlations between the lesion areas and serum concentrations of TGF-β1 and oxLDL. CONCLUSIONS: Ezetimibe alone played the same protection against a moderate atherosclerotic lesion as atorvastatin, which was associated with lowering serum cholesterol, decreasing circulating inflammatory cytokines, and inhibiting macrophage accumulation in the lesions.
format Online
Article
Text
id pubmed-4640821
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46408212015-11-13 Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition Tie, Chunmiao Gao, Kanglu Zhang, Na Zhang, Songzhao Shen, Jiali Xie, Xiaojie Wang, Jian-an PLoS One Research Article BACKGROUND: Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein, the study aimed to test whether ezetimibe alone would exhibit similar effects as statin and the combination therapy would be necessary in a moderate lesion size. METHODS AND RESULTS: ApoE-/- male mice that were fed a saturated-fat supplemented diet were randomly assigned to different therapeutic regimens: vehicle, ezetimibe alone (10 mg/kg/day), atorvastatin (20 mg/kg/day) or combination of ezetimibe and atorvastatin through the drinking water. On 28 days, mice were sacrificed and aorta and sera were collected to analyze the atherosclerotic lesion and blood lipid and cholesterol levels. As a result, ezetimibe alone exerted similar protective effects on atherosclerotic lesion sizes as atorvastatin, which was mediated by lowering serum cholesterol concentrations, inhibiting macrophage accumulation in the lesions and reducing circulatory inflammatory cytokines, such as monocyte chemoattractant protein (MCP-1) and tumor necrosis factor (TNF-α). In contrast to ezetimibe administration, atorvastatin alone attenuated atherosclerotic lesion which is dependent on its anti-inflammation effects. There were no significance differences in lesion areas and serum concentrations of cholesterol, oxidized LDL and inflammatory cytokines between combination therapy and monotherapy (either ezetimibe or atorvastatin). There were significant correlations between the lesion areas and serum concentrations of cholesterol, MCP-1 and TNF-α, respectively. However, there were no significant correlations between the lesion areas and serum concentrations of TGF-β1 and oxLDL. CONCLUSIONS: Ezetimibe alone played the same protection against a moderate atherosclerotic lesion as atorvastatin, which was associated with lowering serum cholesterol, decreasing circulating inflammatory cytokines, and inhibiting macrophage accumulation in the lesions. Public Library of Science 2015-11-10 /pmc/articles/PMC4640821/ /pubmed/26555472 http://dx.doi.org/10.1371/journal.pone.0142430 Text en © 2015 Tie et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tie, Chunmiao
Gao, Kanglu
Zhang, Na
Zhang, Songzhao
Shen, Jiali
Xie, Xiaojie
Wang, Jian-an
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title_full Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title_fullStr Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title_full_unstemmed Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title_short Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
title_sort ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640821/
https://www.ncbi.nlm.nih.gov/pubmed/26555472
http://dx.doi.org/10.1371/journal.pone.0142430
work_keys_str_mv AT tiechunmiao ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT gaokanglu ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT zhangna ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT zhangsongzhao ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT shenjiali ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT xiexiaojie ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition
AT wangjianan ezetimibeattenuatesatherosclerosisassociatedwithlipidreductionandinflammationinhibition